Ta Sung Lee

EQS-News: Lucinda Crabtree to Join MorphoSys as Chief Financial Officer

Retrieved on: 
Donnerstag, März 16, 2023
Research, FSE, Corporate communication, J. P. Morgan, Jefferies, Neil Woodford, University College London, Financial Oversight and Management Board for Puerto Rico, Patient, Ta Sung Lee, Goldman Sachs, Strategic management, Security (finance), Management, Physiology, Pharmacology, MorphoSys

MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Lucinda Crabtree, Ph.D., will join MorphoSys as Chief Financial Officer and member of the Management Board, succeeding Sung Lee.

Key Points: 
  • MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Lucinda Crabtree, Ph.D., will join MorphoSys as Chief Financial Officer and member of the Management Board, succeeding Sung Lee.
  • “I am pleased to welcome Lucinda to MorphoSys as our new Chief Financial Officer,” said Marc Cluzel, M.D., Ph.D., Chairman of the MorphoSys Supervisory Board.
  • “Lucinda will bring a strong skill set to MorphoSys with her broad biotech experience in corporate roles, as an analyst and investment professional, and the impact she has made in leading finance, strategy and investor relations divisions.”
    Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys, added: “Lucinda has achieved tremendous success in designing and executing financial and business transactions.
  • “MorphoSys has successfully honed its focus on oncology and has a strong cash position to execute on their great opportunities.”
    Lucinda Crabtree joins MorphoSys from Autolus Therapeutics, a clinical-stage biopharmaceutical company developing T cell therapies, where she most recently served as Chief Financial Officer.